Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong product sales growth, particularly in the Vascular Interventions portfolio, and a positive response to new product launches. Despite a decrease in IVD revenue, overall financial guidance for fiscal 2024 remains optimistic, with expected revenue growth and cash flow improvements. The partnership with Abbott and consistent demand for SurVeil DCB further support a positive outlook. However, management's reluctance to provide specific details and guidance on international sales may temper expectations slightly, resulting in a 'Positive' sentiment rating.
Key Financial Performance
Total Revenue $32 million, an increase of 18% year-over-year. Growth was driven by the Medical Device segment, which increased 26% to $24.8 million, offsetting a 5% decrease in the IVD segment.
Medical Device Product Revenue $11.1 million, an increase of 40% year-over-year, primarily driven by monthly shipments of the SurVeil drug-coated balloon and increased sales of the Pounce thrombectomy device.
IVD Product Revenue $7 million, a decrease of 6% year-over-year, primarily due to lower sales of substrate products.
Royalty and License Fee Revenue $11.4 million, an increase of 21% year-over-year, driven by $1.4 million in catch-up payments and increased customer utilization of Serene hydrophilic coatings.
GAAP Net Income $250,000, compared to a net loss of $7.7 million in the prior year, reflecting strong revenue growth and lower R&D expenses.
Non-GAAP Net Income $1.1 million, compared to a net loss of $5.6 million in the prior year.
Adjusted EBITDA $4.8 million, compared to an adjusted EBITDA loss of $1.5 million in the prior year.
Cash Flow from Operations $7.4 million, benefiting from a $3.4 million cash tax refund from the IRS.
Product Gross Margin 60.8%, down from 62.6% in the prior year, impacted by under absorption and production inefficiencies as sales of new products increased.
R&D Expense $10.2 million, a decrease of 21% year-over-year, primarily due to lower SurVeil DCB related costs and a spending reduction plan.
SG&A Expense $13.1 million, an increase of 1% year-over-year.
Cash and Investments $40.9 million at quarter end, an increase of $5.8 million during the quarter.
Long-term Debt $29.5 million, unchanged during the quarter.
Access to Additional Debt Capital Approximately $65 million under existing credit agreement.
Operating Highlights
New Product Launches: Surmodics has successfully commercialized four new products: SurVeil DCB, Pounce Venous, Pounce LP, and preside coating.
Product Sales Growth: Product sales in the Medical Device segment increased by 40% year-over-year, primarily driven by the Vascular Interventions portfolio.
Pounce Venous: Pounce Venous has transitioned to a full commercial launch in March 2024 after successful limited market evaluations.
Pounce LP: Pounce LP has also initiated full commercial launch in April 2024, targeting smaller diameter peripheral arterial vessels.
Market Expansion: Surmodics is focused on expanding the adoption of its vascular interventions portfolio, particularly through partnerships with commercial partners like Abbott.
Market Positioning: The company is positioning itself as a leader in the vascular interventions market with innovative products that address significant clinical needs.
Operational Efficiency: Surmodics achieved a significant improvement in profitability, with an $8 million improvement from a GAAP net loss to GAAP net income.
Cash Flow Generation: Generated $7.4 million in cash flow from operations, exceeding expectations.
Strategic Objectives: Surmodics is focused on three strategic objectives: capitalizing on growth catalysts, developing new products, and driving durable revenue growth.
Clinical Evidence: The TRANSCEND trial provided important clinical evidence supporting the effectiveness of SurVeil DCB.
Risk or Challenges
Competitive Pressures: Surmodics faces competitive pressures in the vascular interventions market, particularly with the commercialization of their SurVeil drug-coated balloon and Pounce thrombectomy products. The company must navigate the competitive landscape to ensure successful adoption and utilization of these products.
Regulatory Issues: The company is subject to regulatory scrutiny, particularly regarding the FDA 510(k) clearance for their Pounce Venous device. Any delays or complications in obtaining necessary regulatory approvals could impact product launches and revenue.
Supply Chain Challenges: Surmodics has highlighted the complexities involved in manufacturing drug-coated balloons, which are noted to be among the most difficult interventional devices to produce. Any disruptions in the supply chain could affect their ability to meet demand.
Economic Factors: The company’s financial guidance reflects potential economic factors, including a decrease in expected revenue from SurVeil DCB license fees, which could impact overall financial performance.
Cash Flow Management: Surmodics anticipates a decrease in cash and investments year-over-year, which indicates potential challenges in cash flow management and operational funding.
Market Adoption: The success of new products like Pounce Venous and Pounce LP depends on market adoption, which can be influenced by physician feedback and competitive alternatives available in the market.
Guidance & Outlook
Strategic Objective 1: Capitalize on near-term growth catalysts in vascular interventions portfolio, focusing on SurVeil DCB, Pounce thrombectomy, and Sublime radial access products.
Strategic Objective 2: Facilitate long-term growth by developing and introducing new products, including Pounce Venous and Pounce low profile.
Strategic Objective 3: Drive durable revenue growth and cash flow generation across core medical device, performance coatings, and IVD businesses.
Fiscal 2024 Total Revenue Guidance: Expected to range from $122 million to $124 million, a decrease of 8% to 6%. Excluding SurVeil DCB license fee revenue, expected to range from $118 million to $120 million, an increase of 15% to 17%.
GAAP Loss Per Share Guidance: Expected to range from a loss of $0.90 to a loss of $0.70.
Non-GAAP Loss Per Share Guidance: Expected to range from a loss of $0.67 to a loss of $0.47.
Third Quarter Revenue Guidance: Expected to range from approximately $29.5 million to $30.5 million, a decrease of approximately 44% to 42%.
Year-End Cash and Investments Guidance: Expected to finish fiscal 2024 with approximately $35 million to $38 million in cash and investments.
Capital Expenditures Guidance: Expected up to $5 million.
Shareholder Return Plan
Shareholder Return Plan: Surmodics has not announced any specific share buyback program or dividend program during this earnings call.
Key Q&A
Earnings Word Cloud
SRDX Transcript
The earnings call summary indicates strong product sales growth, particularly in the Vascular Interventions portfolio, and a positive response to new product launches. Despite a decrease in IVD revenue, overall financial guidance for fiscal 2024 remains optimistic, with expected revenue growth and cash flow improvements. The partnership with Abbott and consistent demand for SurVeil DCB further support a positive outlook. However, management's reluctance to provide specific details and guidance on international sales may temper expectations slightly, resulting in a 'Positive' sentiment rating.
The earnings call reveals mixed signals: strong growth in R&D revenue and a significant reduction in net loss are positive, but declining gross margins and cautious guidance for upcoming quarters are concerning. The Q&A highlights early optimism but lacks concrete data on new product impacts, with management avoiding specifics. No strong catalysts like new partnerships or record revenues were mentioned, and guidance suggests a sequential revenue decline. Without market cap data, a neutral prediction is prudent, given the balance of positive and negative factors.
SRDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
